teaser
Merck KGaA announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for
Cladribine Tablets as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).
The company received a refuse to file letter from the FDA for
the Cladribine Tablets NDA in November 2009.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Regulatory filings for Cladribine Tablets are currently under review in a number of other locations including the European Union.
